RxDoctor Payments DataLook up a doctor →

Ann Bass, MD

Neurology · San Antonio, TXNPI 1104925171

Payments from drug & device makers

$12,289,430in general payments, 2019–2025

Across 3,115 payments — averaging $3945.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6.4M
  • Genentech, Inc.$2M
  • Sanofi$1.2M
  • Bristol Myers Squibb$728K
  • F. Hoffmann-la Roche AG$570K
  • EMD Serono, Inc.$316K
  • plus $1.1M from 54 others
$15,991in research payments, 2019–2025

Across 47 payments — averaging $340.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$15K
  • F. Hoffmann-la Roche AG$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis294$6,423,644
Genentech, Inc.83$2,025,336
Sanofi331$1,151,832
Bristol Myers Squibb175$728,194
F. Hoffmann-la Roche AG94$569,641
EMD Serono, Inc.395$315,929
Genentech USA, Inc.263$237,486
TG Therapeutics, Inc.216$215,313
AstraZeneca186$151,208
Amgen(2 entities)157$118,192
E.r. Squibb & Sons, L.L.C.73$91,155
Biogen126$85,941
Sanofi-aventis U.S. LLC14$42,144
Lilly USA, LLC71$37,757
Ares Trading SA4$22,531
Merck Kgaa6$17,900
Novartis Pharma AG4$13,869
Mallinckrodt Hospital Products Inc.34$13,116
Janssen Research & Development, LLC2$5,453
Banner Life Sciences, LLC1$4,560
Hoffmann-la Roche Limited1$4,000
Sanofi US Services Inc.1$2,404
AbbVie(2 entities)100$1,539
Teva Pharmaceuticals USA, Inc.35$749
Acadia Pharmaceuticals Inc41$745
UCB, Inc.23$590
Biohaven Pharmaceuticals, Inc.9$501
Abbott21$489
Pfizer35$462
Neurocrine Biosciences, Inc.14$444
Mallinckrodt Enterprises LLC5$358
Argenx US, Inc.12$350
Livanova USA, Inc.19$339
Sunovion Pharmaceuticals Inc.21$331
Medtronic15$318
Lundbeck LLC16$293
Supernus Pharmaceuticals, Inc.22$287
Grifols USA, LLC13$268
Amneal Pharmaceuticals LLC16$268
Vanda Pharmaceuticals Inc.7$240
GE HealthCare11$235
Biohaven Pharmaceutical Holding Company Ltd.6$200
Eisai Inc.9$192
Merz Pharmaceuticals, LLC6$165
ANI Pharmaceuticals, Inc.8$155
CSL Behring10$155
Takeda Pharmaceuticals U.S.A., Inc.5$139
Novo Nordisk12$136
Jazz Pharmaceuticals Inc.5$134
Johnson & Johnson(2 entities)7$134
MDD US Operations, LLC8$132
Kyowa Kirin, Inc.6$131
Axsome Therapeutics, Inc.4$114
SK Life Science, Inc.6$112
Adamas Pharmaceuticals, Inc.6$105
Upsher-smith Laboratories LLC5$98
Insightec,inc4$85
Octapharma USA, Inc.4$80
Acorda Therapeutics, Inc3$65
Assertio Therapeutics, Inc.4$61

How this compares

$12,289,430 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$607,439
Medicare patients
471
Services billed
16,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →